Biotech Archives - Page 665 of 733

1 minute read

AstraZeneca And Merck Announce Long-Term Follow Up Results From Phase 3 PAOLA-1 And SOLO-1 Trials

September 9, 8:02 AM

Five-year follow-up of the Phase 3 PAOLA-1 trial showed LYNPARZA plus bevacizumab provided a clinically meaningful improvement in overall survival in a subgroup of HRD-positive patients, with 65.5% of patients

AZN

4 minute read

Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

September 8, 6:17 PM

The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for…

ALNY

3 minute read

Intellia Therapeutics Announces Upcoming Investor Event To Present Interim Clinical Data From Ongoing First-In-Human Studies Of NTLA-2002 And NTLA-2001 On September 16

By Benzinga Newsdesk

September 8, 4:02 PM

Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium Event to include interim safety and serum TTR

NTLA

1 minute read

Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

By Vandana Singh

September 8, 2:27 PM

Cara Therapeutics Inc (NASDAQ:CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia…

CARA

1 minute read

Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial

By Vandana Singh

September 8, 2:24 PM

Vistagen Therapeutics Inc (NASDAQ:VTGN) completed an interim analysis of PALISADE-2, its second Phase 3 trial assessing drug candidate PH94B as an…

VTGN

1 minute read

Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

By Vandana Singh

September 8, 1:53 PM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) presented detailed results from the second of two Phase 3 trials (PRIME) evaluating…

REGN

1 minute read

With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium

By Vandana Singh

September 8, 1:50 PM

Cantor Fitzgerald initiated coverage on Actinium Pharmaceuticals Inc (NYSE:ATNM) with an Overweight rating and a price target of $20, almost an upside…

ATNM

1 minute read

Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer

By Vandana Singh

September 8, 1:48 PM

Exelixis Inc (NASDAQ:EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced…

EXEL

1 minute read

Gilead’s Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings

By Vandana Singh

September 8, 1:27 PM

Gilead Sciences Inc (NASDAQ:GILD) announced the overall survival (OS) results from the Phase 3 TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) versus…

GILD

2 minute read

Needham Gives Revance Therapeutics Buy Rating With Note Titled: FDA Approves Daxxify With Anticipated Product Label Differentiation; Raises Price Target From $25 To $35

By Benzinga Newsdesk

September 8, 11:19 AM

https://needham.bluematrix.com/sellside/EmailDocViewer?encrypt=b39360c5-a6d8-49eb-ab7d-06a90478a63f&mim

RVNC